Impact of government subsidies on innovation of Chinese biopharmaceutical firms: Based on kink threshold model

Abstract

Do government subsidies achieve the goals of stimulating firm innovation and macro-regulation? Existing studies have not reached a consistent conclusion. We will study the incentive effect of government subsidies on innovation of biopharmaceutical firms, analyze the optimal interval of government subsidies, and improve the efficiency of government subsidies. Thus, based on kink threshold model using data from Chinese biopharmaceutical listed companies from 2013–2019, this study analyzes the impact of government subsidies on innovation inputs and outputs. Government subsidies can stimulate innovation inputs and outputs of biopharmaceutical firms. Meanwhile, such subsidies have a significant threshold effect on innovation inputs and outputs, and there is an optimal interval effect. Additionally, concerning enterprise ownership, government subsidies have a more significant role in promoting innovation of non-state biopharmaceutical firms. Regarding regional differences, such subsidies have a more significant role in promoting innovation of firms in the less economically developed central and western regions. This study reveals the influence pattern of government subsidies, and provides insights and suggestions to formulate subsidy policies and enhance innovation.

The “heterogeneous” effect of government grants on bank lending

“…Government grants provided to struggling businesses may artificially boost reported earnings and mask true losses, which could skew reported earnings and cause wrong conclusions. Additionally, political ties may weaken with time and government budgets may prevent government grants from being sustained [ 9 ]. As a result, banks should be cautious when making loan choices and may ask for a higher risk premium when a company receives excessive government funding.…”

“…Government grants have been extensively studied, but few notice the difference in different government grants. Little is known about whether such grants may have heterogenous effects [ 9 – 11 ]. Our research aims to fill this gap in the literature.…”

Interplay of Government Support and Foreign Investment in Enhancing R&D in China’s Strategic Sectors

“…Businesses differentiate themselves from one another through their internal core knowledge and unique capabilities, which are valuable, difficult for competitors to imitate, and non-replicable. Their profitability and competitive advantage stem from their enterprise heterogeneity, which is fueled by factors like productivity, enterprise size, ownership, and industry (Jia et al, 2021;Li et al, 2023;Rege & Lee, 2022;Zaman & Zaccour, 2021).…”

Using Linear Regressions Analyzing the Impact of Medical Technology Inputs on Economic Output in China and Brazil

“…In terms of research capacity, China has invested significant resources to the research, development and implementation of medical technologies, which has led to significant progress in research and innovation. In particular, investments and subsidies in digital health, telemedicine, and AI-powered diagnostics have transformed the delivery of healthcare services and led to new trends in many more areas [7]. In addition, China's global health organizations are all at different stages of development, each with their own areas of strength -for example, hemophilia surveillance system for the National Health Commission, malaria and other infectious diseases for the Chinese Center for Disease Control and Prevention, and environmental health for Tsinghua University [8] -compared to Brazil, which has struggled to allocate sufficient funding for medical technology, which has affected the efficiency of its healthcare system.…”